A genetic map of human metabolism across the allele 1 frequency spectrum 2

3

4 Martijn Zoodsma¹, Carl Beuchel¹, Summaira Yasmeen¹, Leonhard Kohleick¹, Aakash

- Nepal¹, Mine Koprulu², Florian Kronenberg³, Manuel Mayr⁴, Alice Williamson^{1, 2}, Maik 5
- Pietzner^{1,2*} & Claudia Langenberg^{1,2*} 6
- 7
- 8 ¹Computational Medicine, Berlin Institute of Health at Charité – Universitätsmedizin 9 Berlin, Berlin, Germany
- ² Precision Healthcare Institute, Queen Mary University of London, London, UK 10
- 11 ³ Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria
- 12 ⁴ National Heart and Lung Institute, Imperial College London, London, United Kingdom
- 13

14

- 15 Corresponding authors:
- 16 Maik Pietzner (maik.pietzner [at] bih-charite.de)
- 17 Claudia Langenberg (claudia.langenberg [at] qmul.ac.uk)
- 18 *These authors contributed equally

Abstract 19

20

Genetic studies of human metabolism identified unknown disease processes and novel 21 22 metabolic regulators, but have been limited in scale and allelic breadth. Here, we provide 23 a data-driven map of the genetic regulation of circulating small molecules and 24 lipoprotein characteristics (249 metabolic traits) measured using protein nuclear 25 magnetic resonance spectroscopy (¹H-NMR) across the allele frequency spectrum in 26 ~450.000 individuals. In trans-ancestry analyses, we identify 29,824 locus-metabolite 27 associations mapping to 753 regions with effects largely consistent between men and 28 women and major ancestral groups represented in UK Biobank. We develop a framework 29 for classifying the observed extreme genetic pleiotropy, enabling identification of upstream 'master' regulators of lipid metabolism ('proportional pleiotropy'), such as 30 31 ANGPTL3. We establish rare-to-common allelic series by integrating machine-learning guided effector gene assignments with rare exonic variant analyses providing high 32 33 confidence gene assignments at >100 loci, including less established regulators of lipid 34 metabolism like SIDT2. At 17 such loci we observed phenotypic heterogeneity among 35 wariants mapping to the same generic is dicating differential match olic sole such the alteriad

36 gene product. We identify *VEGFA* as a potential modulator of HDL-mediated risk for 37 coronary artery disease. Our results demonstrate how rare-to-common genetic variation 38 combined with deep molecular profiling can identify unknown and inform on poorly 39 understood regulators of human metabolism to guide prevention and treatment of 40 diseases.

41 Introduction

42

43 Our understanding of human metabolism is mostly based on dedicated hypothesis 44 testing in experimental settings, informed by model organisms or observations in rare 45 diseases patients. Only recently, high-throughput profiling of small molecules in largescale studies has enabled systematic testing of genetic variation across the genome and 46 47 provided an agnostic approach for the discovery of genes that encode key metabolic 48 regulators¹⁻¹¹. These efforts have provided important new insights into how genetic 49 variation shapes human chemical and metabolic individuality¹ and have corroborated a large body of biochemical knowledge^{1,2,10,12}. 50

51

52 The value of such genome-metabolome-wide association studies (mGWAS) extends 53 beyond the mapping of biochemical pathways, sometimes demonstrating almost They provided examples how readily available 54 immediate clinical value. 55 supplementation strategies may prevent disease or delay onset in high risk individuals, 56 such as serine for the rare eye disorder macular telangiectasia type 2^2 . Others further identified unknown variants affecting the absorption, distribution, metabolism, and 57 excretion of exogenous compounds, most importantly drugs^{1,13}, providing pathways to 58 59 mitigate adverse drug effects. However, there are several challenges that currently limit the potential of mGWAS studies, in particular for causal inference. These include 1) the 60 61 still rather small number of, at most, a dozen genetic variants linked to single molecules, 2) the inability to distinguish whether pleiotropic variants act on different molecules or 62 63 pathways independently (horizontal pleiotropy), or whether they serve as 'root causes' of successive downstream changes (vertical pleiotropy), 3) the difficulty in distinguishing 64 65 between locus-specific and metabolite abundance effects when colocalization at

disease-risk loci is observed¹, and 4) the challenge of confidently assigning effector
genes at newly identified loci.

68

Here, we integrated rare (based on whole exome sequencing) and common genetic 69 70 variation with measures of 249 metabolic phenotypes, including small molecules and 71 detailed lipoprotein characteristics, among >450,000 UK Biobank participants representing three distinct ancestries. We demonstrate largely consistent genetic 72 73 regulation across ancestries and sexes for almost 30,000 locus – metabolite associations 74 and systematically categorise abundant genetic pleiotropy. By integrating machine-75 learning derived effector gene assignments with rare exonic variation, we identify 76 previously unknown regulators of metabolism and observe heterogeneity in association 77 profiles for variants mapping to the same gene. Finally, we demonstrate how systematic integration of statistical colocalization and Mendelian randomization can identify 78 79 pathways with the potential to mitigate cardiovascular disease risk beyond current 80 approaches focused primarily on LDL-cholesterol lowering.

81 Results

82

83 We integrated genome-wide association studies (GWAS; population-specific minor allele 84 frequency (MAF)≥0.5%) with rare exome-wide association studies (MAF≤0.5%) on 85 plasma concentrations of 249 metabolite phenotypes, quantified using ¹H-nuclear 86 magnetic resonance spectroscopy (NMR). We included up to 450,000 UK Biobank (UKB) 87 participants across three major ancestries (British White European – EUR (n=434,646); 88 British African – BA (n=6,573); British Central South Asian – BSA (n=8,796); 89 (Supplementary Fig. 1). The NMR measures provided a detailed readout of lipoprotein particles along a range of lipoprotein sizes containing 14 subclasses (i.e., extra-large very-90 91 low density (VLDL) to small high-density (HDL) lipoprotein particles), along with small molecules such as amino acids and ketone bodies quantified in molar concentration 92 93 units (Supplementary Table 1).

94

95 Common genetic variation underlying circulating metabolites

96 We identified 29,824 regional sentinel-NMR measure associations in trans-ancestral 97 meta-analyses, representing 753 non-overlapping genomic regions (Fig. 1a; 98 Supplementary Table 2). Nearly half of these regions (N=359, 47%) were associated with more than 10 NMR measures, demonstrating considerable pleiotropy cutting across 99 100 metabolite classes for 350 regions. Characteristics of large HDL particles, such as 101 concentration, particle size and (phospho)lipid, cholesterol, cholesteryl ester and 102 triglyceride content, were associated with the largest number of regions (median: 166, 103 IQR: 126-195), compared to median of 105 associated regions observed across all NMR 104 measures (IQR: 68-142). Findings that considerably extended previous work³ and replicated parallel efforts using UK Biobank⁹ (Supplementary Fig. 2). Genes with well-105 106 characterised roles in human metabolism were significantly enriched among the closest 107 genes to regional sentinels across different significance bins (adjusted p-values < 4.24 x 108 10⁻⁹; **Supplementary Fig. 3**). This suggests that ever-larger studies of often considered 109 omnigenic traits, such as metabolites, still yield biological plausible findings and not 110 merely non-specific upstream regulators.

111

112 Almost all regional sentinel associations (n=29,410, 98.6%) showed little evidence of 113 heterogeneity (p>10⁻⁴) across ancestries. To rule out possible artefacts that might have 114 masked ancestral-specific effects (e.g., variant coverage and statistical power in the 115 smaller ancestry groups), we repeated the GWAS within each ancestry separately. 116 Consistent with the trans-ancestral meta-analysis, we observed high correlations of effect estimates for regional sentinels identified in the largest subgroup of White 117 118 European participants when compared to those of African and Central South Asian 119 ancestry (Fig. 1c-d; Supplementary Table 3, Supplementary Fig. 4). Although we note 120 that the limited sample size did not permit comprehensive replication, our ancestry-121 specific analyses also revealed one locus not seen in European participants. The 122 previously reported¹⁴ missense variant rs3211938 within *CD3*6 which is common in 123 people of African ancestry (MAF_{BA}= 0.12) but absent in European ancestry (MAF_{EUR}= 0.0), 124 was significantly associated (p-values < 1.49 x 10⁻¹⁰) with lower plasma concentrations of 125 omega 3 fatty acids and 15 other NMR measures, including lipoprotein particle 126 characteristics. This is in line with the role of CD36 as a fatty acid translocase, facilitating 127 the recognition and uptake of long-chain fatty acids.



129 Figure 1: Common genetic regulation of circulating metabolites. A) Top-down Manhattan plot 130 showing trans-ancestral sentinel variants for 249 metabolic phenotypes at a metabolome-adjusted 131 genome-wide significance threshold of $p < 2.0 \times 10^{-10}$. Each row represents an NMR measure, coloured 132 for biochemical class, chromosomal positions are shown on the x-axis. B) Weighted average allele 133 frequency compared to estimated effect size for trans-ancestral sentinel variants. Points are coloured 134 for biochemical classification. C) Comparison of effect sizes between White European samples (x-135 axis) and British-African samples (y-axis). We considered variants that were significant in either 136 population. D) Similar to C) but comparing British-Central /South Asian samples. Dots are coloured 137 according to their absolute Z-score in White European samples.

138

128

139 Refinement of regional associations through multi-ancestry fine-mapping

We next employed a two-stage strategy to refine regional associations to a small number of candidate causal variants. Firstly, we implemented fine-mapping in the largest group of European-ancestry participants. We then further refined the subset of loci with at least suggestive evidence across ancestries (p<10⁻⁴) using trans-ancestral fine-mapping, leveraging the differential blocks of linkage disequilibrium (LD) despite vastly different sample sizes.

146

147 We first identified 3,007 statistically independent metabolite quantitative trait loci 148 (mQTLs) associated with one or more NMR measure, representing a total of 43,322 credible set – NMR measurement pairs (Supplementary Table 4). This successfully 149 150 defined 16,170 credible sets with a high-confidence variant (posterior inclusion 151 probability (PIP) > 0.5). Among these were low-to-common frequent variants with 152 functional consequences in metabolic genes, such as rs78734745 (MAF=0.8%; 153 PIP=67.9%), a splice donor variant for ME1, associated with plasma citrate levels (beta=-154 0.11; p-value<1.6x10⁻²¹). Lead fine-mapped mQTLs for a given NMR measure explained, 155 on average, 6.9% (range: 0.57% - 13.42%) of the variance in plasma concentrations 156 (Supplementary Fig. 5).

157

158 Secondly, we leveraged the different LD-block structure among participants of British 159 African and British Central South Asian ancestry to further refine a total of 3,336 credible 160 sets that still contained >1 variant and for which the locus had at least suggestive 161 evidence for significance in either ancestry (P < 1.0 x 10⁻⁴). Trans-ethnic fine-mapping led 162 to an increase in the number of credible sets containing high-confidence variants 163 (Europeans: 997, multi-ancestral: 1,794) and decreased the median credible set size 164 from 9 to 4 variants, while increasing the median posterior inclusion probability from 0.06 to 0.16 (Supplementary Fig. 6). This included 1,107 (33.7%) credible sets with two or 165 166 fewer variants, and 1,518 (45%) credible sets that were reduced in size by more than half. We note, however, that most eligible European credible sets were already comparatively 167 168 small (median 9 variants), but sometimes still spanned multiple genes.

169

For example, a signal associated with mono-unsaturated fatty acids (MUFA) concentrations at 17q21.2 contained 76 genetic variants spread across several genes covering a 1Mb window in the European-only discovery. The signal was fine-mapped to as few as 4 variants (two intergenic, one <50kb distance to the gene body) after incorporating evidence from other ancestries (**Supplementary Fig. 6**). Three of these four variants mapped to the *PTRF/CAVIN1* gene, which plays a crucial role in the formation of caveolae that are particularly abundant in adipocytes. Thus, *PTRF/CAVIN1* has been

177 linked to generalized lipodystrophies¹⁵, providing a biologically plausible effector gene at

178 this locus through trans-ancestral refinement of the credible set.

179

180 Sex-differential effects at loci encoding metabolic genes

181 Many aspects of metabolism are known to vary by sex^{16,17}, but only few genetic loci have 182 been identified that may explain such differences^{18,19}. While we observed highly correlated effect sizes across female and male participants (median R²: 0.98, range: 0.90 183 184 - 0.99), we also identified 360 putative sex-differential loci for 239 metabolic traits, 185 representing 1,800 heterogenous associations in sex-stratified meta-analyses 186 (heterogeneity p-value $< 5 \times 10^{-8}$, see **Methods**). To rule out that sex-differential effects 187 could be explained by other factors that differ between the sexes, we performed 188 additional analyses identifying that sex-differential effects at one-third of loci (n=625, 34.7%) were attenuated when controlling for factors such as body mass index, tobacco 189 190 use, alcohol intake, and the use of lipid-lowering or diabetes medication 191 (Supplementary Fig. 7, Supplementary Table 5). For loci unaffected by such additional 192 factors, effect estimates were generally directionally concordant between the sexes but 193 showed differences in magnitude (Fig. 3a). This is consistent with results previously 194 observed for proteomics²⁰ and suggests that the majority of significant sex interactions 195 do not reflect sex-discordant effects. We observed pleiotropic sex-differential loci 196 associated with 30 or more NMR measures near established lipoprotein genes (APOE, 197 APOC1, LPL) but also less established genes (SIDT2), where sex was the most likely modifying factor. These finding may help to better understand sex-specific cut-offs in 198 199 cardiovascular risk assessment in clinical guidelines to initiate treatment with lipid 200 lowering medication²¹. We found *CPS1* on 2q34 to show the strongest sex differences, in 201 line with previous reports¹⁸, with effect sizes for glycine being twice as large in females 202 compared to males (rs1047891, beta females = 0.77, beta males = 0.34 s.d. units).

203

204 Biological reclassification of established 'lipid' loci

To assess the value of metabogenomic studies involving lipoprotein profiling based on ¹H-NMR spectroscopy over standard clinical markers, we systematically classified the NMR metabolome association profiles for 1,657 genetic variants reported for commonly measured clinical markers (LDL-cholesterol, HDL-cholesterol, total cholesterol and

209 triglycerides) by the Global Lipids Genetics consortium (GLGC) in 1.6 million samples²². 210 Around 25% of associated variants had the corresponding NMR measure among the top 211 10% of the most strongly associated NMR measures, with 22.5% of genetic variants 212 showing significantly stronger associations with refined lipoprotein measures compared 213 to their matching measure on the NMR platform, an observation most pronounced for 214 non-HDL and LDL-cholesterol concentrations (Fig. 3b). While this indicated that relevant loci for lipoprotein metabolism can be discovered using readily available clinical 215 216 measurements, it also demonstrates the necessity of refined lipoprotein profiles for 217 better understanding the relevant biological pathways, including any inference about 218 druggability or use for genetic causal inference methods. One such example was the 219 PNPLAP3 locus (tagged by rs3747207, associated with LDL-cholesterol by the GLGC; p = 220 2.3×10^{-21} , beta = -0.014), where we observed no evidence of association with LDL-221 cholesterol (beta=-0.001, p = 0.49) but LDL particle size (beta=0.045, p-value = 1.04×10^{-1} 222 ⁷³), and multiple characteristics of extra-large VLDL particles (**Supplementary Fig. 8**). The 223 intronic rs3747207 variant is in strong LD ($r^2=0.98$) with the well-known missense variant 224 rs738409 (p.I148M) that has been demonstrated to confer hepatic lipid accumulation by 225 altering ubiquniation of patatin-like phospholipase domain-containing protein 3 226 (PNPLA3) encoded by PNPLA3²³. Our results provide human genetic support for a 227 recently proposed role of *PNPLA3* in the secretion of large VLDL particles²⁴. The 228 association with LDL-cholesterol in massive scale studies likely being a distant 229 downstream consequence.

230



Figure 3: Putative sex-differential loci and reclassification of established lipid loci. A) Comparison of effect sizes of putatively sex-differential loci (defined as loci with heterogeneity pvalue $< 5 \times 10^{-8}$ in a meta-analysis across the sexes). B) Rank distributions for each of the five matching NMR traits compared to the Lipids Genetics traits across genetic loci. Per locus – trait combination,

236 205 lipid-related NMR traits were ranked based on their absolute effect size and compared to the NMR
237 trait that corresponds the Lipids Genetics consortium trait. Pie charts show the percentage of loci
238 where the corresponding NMR trait is ranked among the top 10% of associated traits.

239

240 Machine-learning guided effector gene assignment

241 Assigning effector genes to genetic variants remains one of the most important bottlenecks for translating GWAS results into tangible insights. We assigned effector 242 genes for almost three-quarters of European fine-mapped mQTLs (73.6%; n=2,213) with 243 244 at least moderate confidence (candidate gene score \geq 1.5, range 0 to 3), including about 245 28.2% with high-confidence assignments (score≥2; n=848), by training a machine 246 learning model that integrates functional genomic resources with pathway information inspired by the ProGeM framework²⁵ (**Supplementary Table 6**). For example, we 247 248 prioritised the fatty acid elongase gene ELOVL6 for 16 different NMR measures (tagged by 249 rs3813829), including the fraction of cholesterol and other fatty acids on very small VLDL 250 and very large HDL particles in addition to the fraction of saturated fatty acids. The gene 251 product, ELOVL fatty acid elongase 6, catalyses the rate-limiting step in long-chain fatty 252 acid elongation, which are subsequently incorporated into lipoprotein particles. We also 253 prioritized genes with upstream roles in metabolism, including a locus on 17q25.3 where 254 we prioritized cytohesin-1 (CYTH1) as the candidate causal gene for five independent, 255 genetic variants linked to 11 distinct NMR measures mostly comprising characteristics 256 of VLDL particles. *CYTH1*, previously associated with type 2 diabetes²⁶, promotes activation of ADP-ribosylation factors (ARF)1, ARF5 and ARF6, regulators of lipid vesicle 257 258 transport, membrane lipid composition and modification²⁷, demonstrating a relevant but 259 indirect link to lipoprotein metabolism.

260

We observed considerable overlap of machine-learning guided effector gene predictions 261 262 (top three genes) with those reported based on manually curated biological plausibility (191 out of 283 loci)³ or based on colocalization with protein quantitative trait loci that 263 have not been used to train the algorithm²⁸ (81 out of 143; **Supplementary Table 6**). While 264 missing overlap indicates room for improvement, 24 high-confidence assignments did 265 strongly disagree with either external source (gene score >2 but no match among pQTL 266 267 prioritised or manually curated ones). This included a locus on chromosome 19q13.11 268 tagged by rs62102718 for which we prioritised *PEPD* with high-confidence (score=2.42)

as opposed to *CEBPA*³. PEPD encodes peptidase D, highly relevant for collagen turnover,
that has been shown to promote adipose tissue fibrosis in mouse knock-out models and
promoting insulin resistance²⁹. Insulin resistance, in turn, being a very plausible
explanation for the pleiotropic effect of the variant on diverse lipoprotein characteristics
(n=31).

274

275 **Tissue distribution of effector genes**

276 We next tested tissue-specific expression patterns of the identified effector genes to 277 better understand organ sites contributing to (lipoprotein) metabolism. Strong clustering 278 was observed at both the tissue and metabolite levels, reflecting both known and less 279 established organ contributions (Supplementary Fig. 9a, Supplementary Table 7). 280 Genes characteristic of the liver, adipose tissue, adrenal gland, but also female breast 281 tissue (likely reflecting its high adipose tissue content) were significantly enriched among 282 effector gene sets across the metabolic measures captured by NMR. This included 283 significant enrichment of all amino acids in liver tissue (e.g., phenylalanine: odds ratio 284 (OR): 14.8, $p < 1.3 \times 10^{-8}$, histidine: OR 7.9, $p < 2.9 \times 10^{-11}$) but also for skeletal muscle in 285 alanine metabolism (OR:3.82; p-value<7.9x10⁻⁹). Similar enrichments were observed 286 when using the closest gene instead of our annotated effector genes for mQTLs 287 (Supplementary Fig. 9b).

288

289 Modes of metabolic and systemic pleiotropy

290 Pleiotropy is a widespread but poorly understood phenomenon and we developed a 291 framework to characterise four different modes of metabolic pleiotropy for all fine-292 mapped mQTLs (Fig. 4a-d; Supplementary Fig. 10 and Table 6; see Methods). About half of the pleiotropic mQTLs (n=880; ≥2 NMR measures) showed evidence for two 293 294 different modes of vertical pleiotropy. Firstly, within confined pathways (n=218; 'pathway 295 pleiotropy') or, secondly, as a function of the correlation with the 'lead' NMR measure 296 (n=662; 'proportional pleiotropy'; Fig. 4a). For example, rs76594121 tagged an mQTL at 297 3q21.3 associating with different characteristics of large HDL particles, for which we 298 prioritized ACAD9 as the most likely candidate gene (Fig. 4a). The gene product of ACAD9, 299 acyl-CoA dehydrogenase family member 9, is part of complex I of the respiratory chain 300 that catalyses the oxidation of fatty acids with a high affinity for long chain fatty acids that

301 are, amongst others, carried by HDL particles. A prototype example for 'proportional 302 pleiotropy' was an mQTL tagged by rs624698 for which we prioritized ANGPTL3 as the 303 effector gene (Fig. 4b). Angiopoietin-like 3, encoded by ANGPTL3, inhibits lipoprotein lipase activity but also endothelial lipase, resulting in increased triglycerides, HDL-304 305 cholesterol, and phospholipid concentrations, consistent with HDL-particle 306 characteristics being the most strongly associated NMR measures (p<1.0x10⁻⁵⁴⁶). Other 307 associations being downstream effects on lipoprotein metabolism rather than acting on 308 pathways (**Fig. 4b**), considerably expanding independent previous genetic 309 observations³⁰.

310

311 The remaining half of pleiotropic mQTLs showed evidence for two modes of horizontal 312 pleiotropy: those with evidence for 'disproportional pleiotropy' (n=68) and a larger group with evidence for 'nonspecific pleiotropy' (n=720). For example, a small deletion on 313 314 chromosome 1 (chr1:92982441:CA>C) was associated with a highly correlated cluster of 315 NMR measures, including characteristics of IDL, LDL, and VLDL particles (Fig. 4c), but 316 for which we detected no correlation of association strengths according to the lead NMR 317 measure, the concentration of esterified cholesterol in medium-sized VLDL particles 318 (p<6.8x10⁻¹⁴). We prioritized EVI5 as the most likely candidate gene, supported by 319 previous studies on rare functional variants³¹. The gene product of *EVI5*, ecotropic viral 320 integration site 5, has no apparent link to (lipoprotein) metabolism in line with most of the 321 gene assignments for mQTLs with a similar nonspecific pleiotropy pattern. An example 322 of 'nonspecific pleiotropy' was the APOB missense variant rs676210 (p.Pro2739Leu) 323 associated with 126 NMR measures across the entire lipoprotein density range, but also 324 creatinine and glycoprotein acetyl concentrations (Fig. 4d). The differential effects of the 325 same genetic variation on distinct lipoprotein subgroups aligns with changes in lipid 326 profiles seen with mipomersen, an antisense oligonucleotide against APOB, that 327 demonstrated reductions in LDL-cholesterol but also subsequent increases in the 328 triglyceride content of VLDL particles as hepatic adaption occurs³².

329

Modes of molecular pleiotropy only partially translated into pleiotropy across the entire breath of phenotypes and diseases studied genetically (**Fig. 4e**). We observed a two-fold enrichment of 'proportional pleiotropic' (OR: 2.11; p<2.0x10⁻¹⁴) and to a lesser extend an

333 enrichment of 'nonspecific pleiotropic' (OR: 1.52; p<1.1x10⁻⁵) variants among variants 334 reported in the GWAS catalog for ≥5 non-metabolomic trait categories (see Methods). In 335 contrast, the set of pleiotropic GWAS catalog variants was significantly depleted for 'specific' mQTLs (odds ratio: 0.42; p<1.6x10⁻²¹). Some phenotypically specific variants 336 337 thereby provided clues to understand non-specific molecular pleiotropy (Fig. 4f). For example, rs8101064, an intronic variant in INSR, encoding the insulin receptor, has been 338 reported for type 2 diabetes among East Asians³³ and was associated with 40 NMR 339 measures in a nonspecific manner, likely reflecting the broad effects of insulin resistance 340 341 on whole body lipid metabolism. Systemic mechanisms explaining effects of 342 'proportional' and 'nonspecific' pleiotropic mQTLs were further evidenced by a more than 20-fold significant enrichment of associated trait categories such as 'metabolic disease', 343 344 'fatty liver disease', and 'arterial disorders' (Fig. 4g).



345

346 Figure 4: Modes of pleiotropy. a-d) Exemplary scatterplots opposing the squared trait correlation of 347 the lead NMR measure for the listed variant against the absolute Z-score from linear regression 348 models for all associated NMR measures. The colours indicate different modes of pleiotropy and 349 correspond to the legend in e). For each plot, a linear regression fit with 95%-confidence interval is 350 given. e) Number of associated NMR measures for each of 3007 mQTL groups opposed to 351 associations reported in the GWAS catalog after pruning the GWAS catalog for metabolic phenotypes 352 (see Methods). Colouring is according to modes of pleiotropy. f) Scatterplot opposing the number of 353 associated NMR measures (x-axis) of each mQTL group with the number of reported EFO parent 354 categories in the GWAS catalog. g) Odds ratios and 95%-confidence intervals from logistic regression 355 models testing whether EFO categories (x-axis) are more frequently reported for pleiotropic mOTL 356 groups compared to specific ones. Darker colours indicated estimates passing corrected statistical 357 significance.

358

359 **Convergence of common and rare genetic variation shaping metabolism**

360 Previous investigations focussed on either large-scale common variant^{1–4,8} or 361 comparatively small-scale rare exonic variant discovery efforts^{7,34}, but these approaches

362 have not been able to integrate such information at scale to establish allelic series that 363 confidently link genes to metabolites, including previously unknown regulators of 364 metabolism. We identified rare variation (MAF≤0.05%) in a total of 209 genes to be significantly (p< 1.1 x 10⁻⁸) linked to one or more of 249 NMR measures combining ultra-365 rare gene burden analysis (3,709 significant associations; Supplementary Table 8) and 366 367 rare exonic variant analysis (4,131 significant associations; **Supplementary Table 9**). Effect sizes were significantly larger compared to more frequent variant effects (Fig. 5a). 368 369 For example, people carrying rare predicted loss-of-function variants in SLC13A5 had 370 more than 1.4 s.d. units higher plasma citrate concentrations per copy of the possibly 371 damaging allele (beta:1.41; p-value<2.6x10⁻²⁰).

372

373 We also observed considerable pleiotropy, including 47 genes associated with 20 or more 374 NMR measures. Many of these genes have well-known roles in metabolism or small 375 molecule transport, such as half (n=23/51) of the genes being involved in (peripheral) 376 cholesterol metabolism (**Supplementary Fig. 11**). On the other hand, rare pleiotropic 377 variants with large effect sizes (MAF < 0.02% and beta > 0.6 s.d. units) pointed towards 378 less-established regulators of metabolism including SIDT2 (chr11:117186662:C>T, 379 n=124 carriers), JAK2 (chr9:5073770:G>T, n=73 carriers) or CEP164 380 (chr11:117356670:C>G, n=49 carriers). Experimental work already suggested a role for 381 the gene product of SIDT2 (SID1 transmembrane family member 2) in hepatic lipid 382 metabolism and apolipoprotein A1 (ApoA1) secretion, the main protein component of HDL particles which constituted the majority of associated NMR measures (Fig. 5b)^{35,36}. 383 384 In contrast, associations with JAK2 variants indicate a link to clonal haematopoiesis of indeterminate potential (CHIP)³⁷ with uncertain causality. 385

386

We observed strong overlap between our gene burden and common variant findings, with 85.4% of rare variant (n=3528) and 75.5% of gene burden (n=2802) associations being no more than 100kb away from the nearest statistically independent lead credible set variant (**Fig. 5c**). In contrast, most common variant findings (92.3%) were not within 500kb of matching rare variant/burden evidence . Notably, 12.1% of gene burden results were more than 1Mb away from the next common credible set variant for the respective

NMR measure, aligning with recent observations that both approaches partly prioritise
 different genes³⁸.

395

At 116 genes (55.5%), rare variant and/or burden evidence overlapped with effector gene 396 397 predictions for closeby common credible set variants (≤200kb) for one or more 398 associated NMR measure (Fig. 5d), providing independent support for allelic series (Fig. 5d; Supplementary Table 10). For example, we identified an allelic series composed of 399 400 7 rare loss-of-function (LoF), 1 gain-of-function (GoF), and 4 common variants for serum 401 citrate levels at *SLC13A5* encoding a sodium-dependent citrate co-transporter. Another 402 allelic series at ANKH comprised four common variants (rs185448606 – MAF=1.3%; 403 rs17250977 – MAF=4.0%; rs826351 – MAF=44.3%; rs2921604 – MAF=45.9%) and a rare 404 missense variant chr5:14745916:T>C (MAF=0.0069%) being also associated with lower 405 serum concentrations of citrate (beta=-2.18 s.d. units, p<5.2x10⁻¹¹) (Fig. 5d). ANKH 406 encodes for a multipass transporter, recently shown to transport citrate³⁹, with an 407 important role in bone health³⁹.

408

409 We observed evidence that genetic variants even within an allelic series had differential 410 metabolic consequences, covering a total of 17 genes associated with ≥10 NMR 411 measures (**Supplementary Table 10**). The most outstanding example included 7 variants 412 (5 rare; 2 common) and a cumulative burden of rare predicted LoF variants mapping to 413 APOA1. They distinctively associated with one or more of 87 NMR measures, most strongly with diverse characteristics of HDL particles of which the gene product, 414 415 Apolipoprotein A1 (ApoA1), is the major component (Fig. 5e-f). This included four rare 416 missense variants (MAF≤0.03%) encoded in exon 4 that each had partly differential effects on the number, size, and cholesterol content of HDL particles (Fig. 5e). Only one 417 418 of which (p.Leu158Pro) primarly associated with serum ApoA1 concentrations and HDL 419 particle number, micking the association with the cumulative burden of high-confidence 420 predicted LoF variants in APOA1, suggesting a potentially dysfunctional protein that lacks 421 interaction with lecithin cholesterol acyl transferase to facilitate cholesterol uptake⁴⁰. In 422 contrast, p.Lys131del and p.Arg201Ser seemed to rather predispose to a shift in 423 cholesterol content from large towards small HDL particles, a pattern opposed by 424 p.Asp113Glu (Fig. 5e). An observation consistent with amyloid formation by ApoA1 that

has been observed in early case reports of p.Lys131del (historically the ApoA-I_{Hetsinki}⁴¹) in
which HDL-cholesterol or ApoA1 concentrations are only mildly changed but aggregation
of misfolded ApoA1 protein can confer organ damage later in life⁴²). Since p.Asp113Glu
and p.Arg201Ser have not yet been identified to cause amyloidosis, we cannot rule out
the possibility that each variant maps to distinctive parts of ApoA1 with subsequently
different consequences on function and/or stability (Supplementary Fig. 12).



433 Figure 5 Rare coding variation associated with NMR measures and convergence with common 434 variant associations. a) Effect estimates against minor allele frequency (MAF) of significantly 435 associated gene burden (diamonds; $p<1.2x10^{-8}$ and rare exonic variants (MAF<0.05%; circles; p<2.0436 x 10^{-10}). b) Effect estimates and -log10(p-values) for associations of the rare intronic variant 437 chr11:117186662:C>T within SIDT2 across all 249 NMR measures. The dotted horizontal line indicates 438 the multiple testing threshold ($p < 2.0 \times 10^{-10}$). c) Genomic distance between gene burden (blue) or rare 439 exonic variants (orange) towards the next common credible set variant. d) Evidence for allelic series 440 based on i) gene burden analysis (bottom panel), ii) rare exonic variants (middle panel), and iii) 441 common variants with prioritized effector gene matching to the evidence from exonic analysis. For 442 each gene, only the NMR measure most significantly associated with the strongest common variant 443 is shown in case multiple NMR measures were associated. Some bars for the number of associated 444 rare exonic variants have been capped to fit into plotting margin but the number is given in the plot. e) 445 Effect estimates (dots) and 95%-confidence intervals for 7 variants mapping to APOA1 as well as a 446 cumulative burden of high-confidence pLOF variants within APOA1 and bespoke circulating measures 447 of ApoA1 and HDL particles (colour gradient). f) The top displays a heatmap of standardized effect 448 estimates (per variant) across 87 NMR measures for each associated variant and a cumulative burden 449 within APOA1. Variants mapping into the region encoding the protein are surrounded by a rectangle. 450 Variant effects have been aligned to the minor allele. The middle panel maps the corresponding 451 variants to their respective transcripts encoding different forms of APOA1, while the lowest panels 452 maps missense variants onto the amino acid sequence of the protein. Variant names coloured 453 similarly had highly correlated association profiles.

454

455 Phenotypic consequences of rare variation in metabolic genes

456 Rare inborn errors of metabolism are among the few disorders screened for at birth by 457 most healthcare systems globally, as early intervention - such as appropriate 458 substitution or dietary regimens – can prevent developmental issues and diseases later 459 in life. We observed a more than 3-fold enrichment of genes previously linked to 460 Mendelian diseases⁴³ ('OMIM genes') among those associated with NMR measures in 461 gene burden and rare exonic variant analyses (odds ratio: 3.30; p-value<6.5x10⁻¹⁷; 462 Supplementary Table 11), in line with results reported from previous mGWAS^{1,2,7,8}. For 463 15 out of 106 genes, we found evidence of significantly associated disease risk ($p<7.5x10^{-1}$ 464 7), largely replicating signs and symptoms of corresponding rare disorders 465 (Supplementary Table 12). Associations with NMR measures thereby represented 466 different modes of action. For cardiovascular diseases, most prominently familial 467 hypercholesterolemia (e.g., via APOB), they likely acted as mediators, whereas 468 associations converging on PKD1 for cystic kidney disease likely indicated disease consequences. We further observed less understood pleiotropic roles of OMIM genes. 469 470 For example, rare predicted loss-of-function variants within SMAD6 are known to cause, 471 amongst others, malformations of bones, e.g., Craniosynostosis 7, characterised by

472 malformations of the skull and subsequent brain damage, and we observed a strongly 473 increased risk for other disorders of the cervical region (OR:28.8; 95%-CI: 10.3 – 80.5; p-474 value<1.4x10⁻¹⁰), as well as significantly smaller VLDL particles (beta:-0.13; 95%-CI: -0.16) - -0.09; p-value< 1.5x10⁻⁹) among rare variant carriers in UKB. The gene product, SMAD 475 476 Family Member 6, suppresses TGF-beta signalling, which has known effects on bone 477 morphogenetic proteins⁴⁴. Independent evidence suggests that *SMAD6* downregulation reduces the expression of core genes involved in lipoprotein metabolism, such as LDLR 478 479 ⁴⁵, that may explain the disease-unrelated association.

480

When we tested more generally whether a rare variant burden in metabolic genes was associated with disease susceptibility, we observed a significant enrichment among susceptibility genes for endocrine and metabolic disorders, such as type 2 diabetes and different lipidemias but not among other disease categories (**Supplementary Fig. 13**).

485

486 Risk mitigation of atherosclerotic cardiovascular disease beyond LDL-cholesterol

487 The success of LDL-cholesterol-lowering drugs for the prevention of atherosclerotic 488 cardiovascular disease (ACVD) can be effectively recapitulated by genetic evidence. 489 Genetic predisposition to high LDL-cholesterol is strongly associated with an increased 490 risk of ACVD ('level effect'), and genetic variations that mimic potent drug targets, such 491 as at PCSK9, show strong evidence of shared effects on both LDL-cholesterol and ACVD 492 ('locus effect')⁴⁶. To identify potential pathways to mitigate the residual risk not addressed by lowering of LDL-cholesterol⁴⁷, we systematically integrated outcome data across 25 493 494 CVD phenotypes⁴⁸⁻⁶², including non-atherosclerotic diseases to test specificity of 495 disease associations, with NMR phenotypes and assessed the convergence of locus and 496 level effects (Supplementary Table 13).

497

We identified significant evidence (false-discovery rate (FDR)<5%) for 1,146 'level effects'
across 218 NMR measures with one or more of 22 CVD phenotypes using pleiotropy
curated genetic instuments in Mendelian randomization (Fig. 6a; Supplementary Table
14). Independently, we observed evidence for 5,527 'locus effects', establishing a shared
genetic architecture (posterior probability (PP)>80%) between 87 mQTL associated with
247 NMR measures and 17 CVD phenotypes (Fig. 6b; Supplementary Table 15). For a

total of 46 NMR measure – CVD combinations we found converging evidence for leveland locus-effects, including 23 not associated in our study with parameter of LDLmetabolism (see Methods; Fig. 6b), providing potential alternatives for addressing
residual risk (Supplementary Table 16).

508

509 For example, we observed robust evidence that, among other measures related to HDL 510 size and composition, genetic susceptibility to larger HDL particle size was associated 511 with a 35% reduced risk of coronary artery disease (CAD; odds ratio=0.65; 95%-CI: 0.50 512 -0.83; $p_{adi}<0.007$, Fig. 6c) along with robust evidence of a shared and directionally 513 concordant genetic signal tagged by rs4711750 at the VEGFA locus (PP = 99%, Fig. 6e). The locus has previously been implicated in CAD risk⁴⁸, and our results now suggest that 514 515 one likely pathway to modulate CAD risk might be via HDL particle size or characteristics 516 of large HDL particles not captured by HDL-cholesterol. Vascular endothelial growth 517 factor A (VEGFA), encoded at VEGFA, is primarily known for its role in angiogenesis⁶³, but 518 it has also been described as a regulatory factor of transendothelial transport of 519 esterified cholesterol from HDL but not LDL particles via activation of scavenger receptor 520 BI (SR-BI) during reverse cholesterol transport⁶⁴. Inhibition of VEGFA is a major 521 pharmaceutical target to suppress vascularisation of malignant tumours⁶³, and agents 522 targeting VEGF signalling are well-known for adverse cardiovascular effects⁶⁵, suggesting 523 that activation of VEGFA, rather than inhibition, might be necessary to potentially reduce 524 CAD risk. Our observations contribute to a growing body of evidence that more tailored 525 approaches - rather than increasing HDL cholesterol content – will likely be needed for 526 potential cardiovascular benefits, given the discouraging trials for most agents increasing HDL-cholesterol⁶⁶. We note, however, that HDL-particle size might still only be a 527 528 'measurable' surrogate, rather than being the true underlying mechanism. For example, 529 inhibition of reverse cholesterol transport via dysfunctional SR-BI increased HDL particle 530 size as well as CAD risk⁶⁷.





532 Figure 6 Genetic prioritisation to target residual cardiovascular risk. a) Summary of two-sample 533 Mendelian randomization analysis testing for putatively causal effects of NMR measures on the risk 534 on diverse cardiovascular diseases (CVD). Shown are effect estimates for NMR - disease pairs 535 passing multiple testing. Metabolites are coloured according to the scheme from Figure 1. b) Locus -536 disease network highlighting loci for which at least one NMR measure showed evidence of 537 colocalization with one or more CVDs (PP≥80%). Only loci without evidence for unspecific pleiotropy 538 are depicted. Loci were annotated with the most likely causal gene. Loci coloured in blue showed 539 evidence for being associated with LDL-Cholesterol whereas red did not. c) Dose-response plot for 540 SNPs associated with HDL particle size (after filtering for pleiotropic SNPs) against the risk for 541 coronary artery disease. Effect estimates (dots) and 95%-Cis are given and MR-regression lines 542 added. d) Effect of rs4711750 across the NMR metabolome. e) Locuszoom plot centred around

543 *VEGFA* demonstrating colocalization for the genetic signal for HDL particle size and coronary artery544 disease.

545

546 **Disease-wide Mendelian randomization screen for non-lipoprotein measures**

Having established categories of pleiotropy for mQTLs beyond simple association counting, we finally aimed to demonstrate its application in a disease-wide screen using 1394 disease outcomes from the FinnGen study⁶⁸ (relase 11) for non-lipoprotein measures. We observed a strong decline, 29 to 13 metabolite – disease association with significant evidence (adjusted p-value < 0.05) from two-sample MR ('level effect') once subsetting to metabolite-specific instruments, indicating false-positive results due to pleiotropy (**Supplementary Table 17**).

554

555 We observed evidence for convergence of locus and level convergence for a risk-556 increasing effect of genetically predicted plasma glycoprotein acetyl concentrations on 557 type 2 diabetes risk (odds ratio per 1 s.d. increase: 1.67; p-value< 3.9×10^{-7}). The association persisted even after additional exclusion of variants with evidence for 558 559 pleiotropy in the GWAS catalog (odds ratio: 1.69; p-value<9.1x10⁻⁵). Notably, 'locus' 560 convergence was based on the consistent effect of the rare loss-of-function variant chr20:44413714:C>T (MAF = 0.02%) within HNF4A on plasma glycoprotein acetyl 561 concentrations (beta: 0.60; p-value<8.3x10⁻¹⁵) and the cumulative effect of ultra-rare 562 563 loss-of-function variants on type 2 diabetes risk (odds ratio: 2.68; p-value: 6.5x10⁻¹⁰). However, we note that plasma glycoprotein acetyl concentrations proxy a complex 564 chronic inflammatory state⁶⁹ warrants further follow-up analysis to establish 565 566 mechanistic links to type 2 diabetes. In contrast, previously reported associations 567 between genetically predicted levels of branched-chain amino acids and type 2 diabetes 568 reached at best nominal significance with a smaller effect size than previously 569 estimated⁷⁰ (e.g., plasma leucine concentrations: odds ratio per s.d. unit: 1.19; p-570 value<0.02).

571 Discussion

572

573 The genetic basis of circulating metabolites provides insights into the complexion of 574 human metabolomic regulation and its subsequent influence on health and disease. By

575 integrating common and rare genetic variation with circulating metabolite 576 concentrations in 450,000 individuals from three different ancestries, we provide here a 577 data-driven map of the circulating metabolome across the allele frequency spectrum. 578 This map identifies previously unrecognized modulators of metabolism with potential 579 health implications.

580

By combining ML-guided common variant-to-gene annotation with rare exonic variation, 581 582 we provided high-confidence effector gene assignments at >100 loci, including some 583 with less establised roles in (lipoprotein) metabolism, such as SIDT2. These findings 584 present compelling candidates for further functional studies, with a strong incentive that 585 they are likely relevant to human biology, in contrast to species differences frequently 586 encountered in animal models^{71,72}. Large-scale studies similar to ours, but with a broader coverage of the plasma metabolome, will likely uncover many more genes with yet 587 undefined roles in metabolism, complementing hypothesis-driven research in 588 589 experimental models.

590

591 After more than two decades of GWAS, it has become clear that pleiotropic effects of 592 genetic variants are ubiquitous (see, e.g., ⁷³). Little distinction has been possible beyond 593 the generic concepts of 'vertical' and 'horizontal' pleiotropy or measures of simple 594 counting. We refine these concepts by observing variants associated with dozens of NMR 595 measures but consistent with the concept of effects diluting/propagating along pathways ('proportional pleiotropy'). Conversely, we also observe variants associated with 596 597 comparatively few NMR measures in an inconsistent pattern ('disproportional 598 pleiotropy') suggesting distinct effects on otherwise highly correlated traits. Our data-599 driven approach thereby augments previous concepts focussed around biochemical 600 pathways reporting directionally discordant pleiotropy to discover metabolic bottlenecks 74. 601

602

Disturbance in metabolism or rearrangements thereof are a hallmark of many diseases, including those not classically considered as 'metabolic', such as eye disorders², but whether these are pathways for prevention or intervention rather than a consequence of the disease remains often elusive in humans. We demonstrated considerable overlap

607 between mQTLs with disease risk loci, including rare-to-common allelic series that can 608 reveal unknown effector genes. However, many such 'locus effects' were characterised 609 by nonspecific pleiotropy, implicating the plasma metabolite as a bystander rather than 610 cause of the disease. This observation aligns with the relatively few notable exceptions, such as HDL particle characteristics and CAD, from two-sample MR analyses that 611 612 contrasted the broad spectrum of observed disease-associations described for the same NMR platform⁷⁵. These observations might be best explained by the concept of metabolic 613 614 flexibility, which includes built-in redundance in key pathways to combat various intrinsic 615 and extrinsic perturbations.

616

617 An important distinction of our study compared to most previous efforts was the 618 availability of highly standardized measurements in a well-designed single large cohort, mitigating influences of preanalytical variables and enabling analyses of even ultra-rare 619 620 variants. However, this also meant that we had little opportunity to investigate the 621 influence of different states of metabolism on our genetic results (such as an overnight 622 fast) or investigate robustness of findings in different enviroments or at scale in other 623 ancestries. For example, UKB participants were not asked to fast overnight prior to their 624 baseline visit, which has been shown to impact genetic findings³. Consequently, sentinel 625 variants capture relatively little variance (0.57% - 1.07%) in circulating ketone body 626 concentrations that are highly dependent on the time since last food consumption. Other 627 limitations included the sensitivity and coverage of the ¹H-NMR platform, and future efforts are likely to reveal more diverse phenotypic consequences of genetically 628 629 constrained flexibility of human metabolism. Another technical aspect to consider in the 630 interpretation of our results is the indirect nature of ¹H-NMR derived measurements of 631 certain analytes, including apolipoproteins, that may have no longer be reliable in the 632 presence of rare damaging variants that change the properties of apolipoproteins as 633 observed for ApoA1.

634 Acknowledgements

The authors acknowledge the Scientific Computing of the IT Division at the Charité Universitätsmedizin Berlin for providing computational resources that have contributed
to the research results reported in this paper
(https://www.charite.de/en/research/research_support_services/research_infrastructur

639 e/science_it/#c30646061). We acknowledge Nightingale Health Plc for access to the UK 640 Biobank NMR biomarker data. We are deeply grateful to the participants, investigators 641 and teams of the UKB and FinnGen studies. We thank Benjamin Wild for assistance in 642 data processing and helpful discussions. This work was supported by DZHK (German 643 Centre for Cardiovascular Research) and BMBF (German Ministry of Education and 644 Research) grants to C.L. and co-funded by a European Union grant to M.P (ERC, GenDrug, 645 101116072). Views and opinions expressed are however those of the author(s) only and 646 do not necessarily reflect those of the European Union or the European Research 647 Council. Neither the European Union nor the granting authority can be held responsible for them. The funders had no role in study design, data collection and analysis, decision 648 649 to publish or preparation of the manuscript.

650 Author Contributions Statement

- 651 Conceptualization: MZ, MP, CL
- 652 Data curation/Software: MZ, CB, YS, LK, MP
- 653 Formal Analysis: MZ, CB, YS, LK, AW, MP
- 654 Methodology: MZ, CB, YS, LK, MK, AW, MP, CL
- 655 Visualization: MZ, CB, LK, AW, MP, CL
- 656 Funding acquisition: CL, MP
- 657 Project administration: CL
- 658 Supervision: MP, CL
- 659 Writing original draft: MZ, CB, YS, MP, CL
- 660 Writing review & editing: MZ, CB, YS, LK, MK, FK, MM, AW, MP, CL
- 661 Competing Interests Statement
- 662 None of the authors declare a conflict of interest.

663 Data availability

- All individual-level data is publicly available to bona fide researchers from the UK Biobank
 (<u>https://www.ukbiobank.ac.uk/</u>). Full summary statistics for all analyses are publicly
 available through the NHGRI-EBI GWAS Catalogue (see Github repository for GWAS
 Catalogue identifiers).
- 668

669 Code availability

Code for the main analyses is freely available on Github (<u>https://github.com/comp-</u>
 <u>med/ukb-mgwas</u>) and permanently archived on Zenodo
 (doi.org/10.5281/zenodo.14716599).

- 673 Methods
- 674 Study design

676 UK Biobank is a prospective cohort study from the UK that contains more than 500,000 677 volunteers between 40 and 69 years of age at inclusion. The study design, sample characteristics, and genotype data have been described elsewhere^{76,77}. The UKBB was 678 679 approved by the National Research Ethics Service Committee North West Multi-Centre 680 Haydock and all study procedures were performed in accordance with the World Medical 681 Association Declaration of Helsinki ethical principles for medical research. We included 682 460,036 individuals across the three major ancestries in the UK Biobank in our analyses 683 for whom inclusion criteria (given consent to further usage of the data, availability of 684 genetic data, and passed quality control of genetic data) applied. Data from the UKBB 685 were linked to death registries and hospital episode statistics (HES). We used the 686 ancestry assignments as defined by the pan-UKB⁷⁸, and further made an effort to assign 687 unclassified individuals to their respective ancestries based on a k-nearest neighbour 688 approach using genetic principal components. All analyses were conducted under UKBB 689 application 44448 and 30418.

690

Metabolomic measurements 691

692

693 Up to 249 targeted metabolomic measurements were quantified using the Nightingale 694 NMR platform in human EDTA plasma samples. Detailed experimental procedures for the NMR platform are described elsewhere^{75,79}. The NMR platform covers a wide range of 695 696 metabolic biomarkers, including lipoprotein lipids, fatty acids as well as small molecules 697 such as amino acids, ketone bodies and glycolysis metabolites. All metabolites are 698 quantified in molar concentration units. We combine here three data releases that cover 699 the full breadth of the UKBB. Metabolomics data was available for 482276 individuals, 700 including 19699 samples with data from both the baseline and repeat visit.

701

702 Metabolites were reliably detected, with only one biomarker over 2.5% missingness in 703 releases 1/2 (creatinine) and release 3 (3-Hydroxybutyrate). 98% of the samples had < 5% 704 missingness over all biomarkers in releases 1/2 and release 3. We used the *ukbnmr*⁸⁰ R 705 package (v2.2, R v4.3.2) for quality control and removal of technical variation in the NMR 706 data. This includes technical confounders such as sample preparation time, shipping 707 plate well, spectrometer effects, time drift within spectrometers and outlier plates.

708

709 We removed samples that were flagged by Nightingale for poor quality and used the MICE 710 (Multivariate Imputation by Chained Equations)⁸¹ R package to impute the remaining 711 dataset. In total, we imputed 0.16% and 0.17% of data in releases 1/2 and release 3, 712 respectively.

713

714 We observed overall good consistency with the overlapping routine blood biomarkers 715 previously measured in the same cohort (median R^2 : 0.9, range: 0.62 – 0.94) 716 (Supplementary Fig. 14).

717

Adjustment of metabolomic data for medication use 718

720 We sought to adjust the NMR data for medication use, especially cholesterol-lowering 721 medication to avoid false positive results driven by medication use in downstream 722 genetic analyses. For male and female participants separately, we fitted linear models to 723 quantify the impact of 6 drug categories on each NMR phenotype: cholesterol-lowering 724 medicine, blood pressure medication, diabetic medication including Metformin usage, 725 oral contraceptive pill or minipill (female only), hormone replacement therapy (female 726 only) (UKB fields 6177 and 6153) (Supplementary Fig. 15, Supplementary Table 18).

727

728 We used data from individuals with both baseline and repeat assessment metabolic data 729 available and estimated the effect of medication in individuals that did not take any drugs 730 at the time of the baseline visit (N = 6,312 male, N = 6,713 female participants). We fitted 731 a linear model predicting the follow-up metabolic data from baseline metabolic data, 732 sex, age and medication use:

733 734

735

NMR_{baseline} ~ NMR_{follow-up} + age + bmi + med_{cholesterol} + med_{diabetic} + med_{contraception} + med_{hormone} + error

736 We note that the sample sizes for diabetic medication ($N_{male} = 45$, $N_{female} = 29$), oral 737 contraceptive medication (N = 27) and hormone replacement therapy (N=148) were too 738 small to reliably estimate any effects. Effect estimates for diabetic medication were 739 correlated to estimates for cholesterol-lowering medicine. The effect estimates for blood 740 pressure medication were minimal across the phenotypes. We considered thus only the 741 impact of cholesterol-lowering medicine and corrected the metabolic data in a sex-742 specific manner.

743

Genotyping and GWAS analyses 744

745

746 GWAS was performed on 249 metabolic traits measured by the NMR platform on 747 European (n = 434,646), British-Asian (n = 8,796) and British-African participants (n=6,573) that had complete phenotypic, covariate and genetic information available. We 748 749 performed GWAS under the additive model using REGENIE (v3.2.5)⁸² that employs a two-750 step procedure to account for population structure. We derived a set of high-quality 751 genotyped variants per population by applying following filters: (MAF > 1%, MAC > 100, 752 missingness rate < 10%, pHWE > 10^-15). Further, linkage disequilibrium pruning was 753 performed using a 1000 kb window, shifting by 100 variants and removing variants with 754 $LD(r_2) > 0.8$. We used these variants as input for the first step of REGENIE, to generate 755 individual trait predictions using the leave-one-chromosome-out scheme. These 756 predictions are used in the second step where individual variants are tested. Models were 757 adjusted for age, sex and the first ten genetic principal components. We tested variants 758 with a minor allele frequency > 0.5%, amounting to 11.5M variants in European 759 individuals, 11.5M variants in British-Asian individuals and 19.3M variants in British-760 African individuals.

761

For initial discovery, we performed a meta-analysis across the three ancestral groups 762 763 using METAL⁸³. We required variants to be present in at least two ancestral groups. To 764 declare significance, we considered a stringent p-value threshold (2.0×10^{-10}) by dividing

the standard genome-wide threshold by the number of metabolic phenotypes (5.0×10^{-8}) / 249).

767

We tested our results for genomic inflation and calculated the SNP-based heritability
 using LD-score regression (LDSC)⁸⁴ (Supplementary Table 19).

770

771 Regional clumping and fine-mapping

772

We used regional clumping (±500kb) around sentinel variants from the analyses
including White European samples to select independent genomic regions associated
with a metabolic phenotype and collapsed neighbouring regions using BEDtools
(v2.30.0). We treated the extended MHC region (chr6:25.5-34.0Mb) as one region.

777

778 Within each region of interest, excluding the MHC region, we performed statistical fine-779 mapping for all phenotypes associated with that region using the 'Sum of single effects' 780 model (SuSiE) implemented in the susieR (v0.12.35) R package⁸⁵. Briefly, SuSiE employs 781 a Bayesian framework for variable selection in a multiple regression problem with the aim to identify sets of independent variants each of which likely contains the true causally 782 783 underlying genetic variant. We implemented the workflow using default prior and 784 parameter settings, apart from the minimum absolute correlation, which we set to 0.1. 785 Since SuSiE is implemented in a linear regression framework, we used the GWAS 786 summary statistics with a matching correlation matrix of dosage genotypes instead of 787 individual level data to implement fine-mapping (susie_rss()) as recommended by the 788 authors⁸⁵.

789

790 Within a given region, a phenotype can be associated to multiple, independent genetic 791 loci. To determine the appropriate number of credible sets, we iterated over the 792 maximum credible sets parameter in susieR from two to ten, thus generating fine-793 mapped results constrained to a range of maximum number of credible sets. For each 794 collection of credible sets, we pruned sets where the lead variant was correlated to the 795 lead variant of other credible sets ($R^2 > 0.25$). After pruning, we considered the fine-796 mapped results constrained to the largest number of credible sets that still contained 797 one or more credible sets.

798

799 We performed several sensitivity analyses by computing joint models per locus phenotype combination. We obtained all lead variants across the credible sets provided 800 801 by SuSiE based on posterior inclusion probability and fitted a single linear model, jointly 802 modelling the effect of all distinct credible sets in the locus for a given phenotype. 803 Subsequently, we retained only credible sets where the lead variant reached genome-804 wide significance ($p = 5.0 \times 10^{-8}$) in both marginal and joint statistics. Furthermore, we 805 ensured the estimated coefficients were directionally concordant and of similar 806 magnitude between joint and marginal models (± 25%). Linear models were 807 implemented in R using the glm() function and used only unrelated white-European 808 participants and the same set of covariates as described above. 809

Finally, we used LD-clumping ($r^2 > 0.6$) to identify credible sets shared across metabolic phenotypes.

812

We computed the correlation matrix with LDscore v2.0 using genetic data from 50,000 randomly selected, unrelated White European UKB participants. In situations where SuSiE did not deliver a credible set, we used the Wakefield approximation⁸⁶ to compute

- 816 95%-credible sets.
- 817

818 Multi-ancestry finemapping

819

820 We aimed to use ancestrally diverse genetic data to refine the credible sets identified in 821 the White European analyses. For 35577 credible sets that contained two or more 822 variants in the European analyses, we checked for evidence of a genetic signal in the 823 British-African and British-Central/South Asian ancestries ($P < 1.0 \times 10^{-4}$) at the same 824 locus (±25kb on either side of the credible set). After these filters, we considered 6979 825 credible sets for finemapping across ancestries using MultiSuSiE⁸⁷. We considered only 826 quality-controlled variants that were prevalent in all populations (MAF>0.5%) and used 827 the posterior inclusions probabilities from the European analyses as priors. LD matrices 828 were calculated from a random subset of 50,000 White European participants for 829 Europeans, and using all available individuals for the British-African and British-830 Central/South Asian ancestries.

831

832 Replication of genetic associations

833

834 We replicated our trans-ancestral genetic signals using two independent studies: i) the 835 so-far largest published mGWAS³, and ii) a parallel effort using overlapping UK Biobank 836 data⁹, both using the same NMR platform. We considered a set of metabolic traits that 837 were directly measured by the NMR platform and not inferred from other traits to avoid 838 multiplicative errors in these more sensitive phenotypes. In total, we were able to match 839 144 (Karjalainen et al) and 169 (Tambets et al) metabolic traits, for which we compared 840 sentinel variants that passed metabolome-adjusted, genome-wide significance in our 841 trans-ancestral meta-analysis and that overlapped between the studies.

842

843 Sex-specific genetic analyses

844

845 To assess whether our genetic analyses were driven by sex differences and whether our 846 results were transferrable to both sexes, we performed sex-stratified GWAS within the 847 largest ancestry (EUR). We defined 'female' and 'male' sex including participants where 848 the recorded sex and sex chromosomes aligned (XX for females and XY for males). The 849 recorded sex was self-reported, and it was not possible to distinguish sex from gender. 850 We acknowledge the importance of distinguishing between sex and gender in research 851 and that chromosomal make-up does not always align with self-identified gender. In 852 total, phenotypic, covariate and genetic data was fully available for 198,796 males and 853 235,850 females. GWASs were performed using REGENIE as described above. Per

854 metabolic trait, we meta-analysed the sex-stratified results using the inverse-variance 855 weighted model in METAL (v2020-05-05)⁸³ and finally clumped results on the 856 heterogeneity p-value using plink (v2.00)⁸⁸ (--clump-p1 5 x 10⁻⁸, --clump-r2 0, --clump-kb 857 2500). We considered loci putatively sex-differential if the meta-analysis heterogeneity 858 p-values were genome-wide significant (p < 5 x 10⁻⁸). We performed additional sensitivity 859 analyses on the putatively sex-differential loci by assessing the influence of covariates 860 approximate the approximate the sense of the performed additional sensitivity 861 analyses on the putatively sex-differential loci by assessing the influence of covariates 862 approximate the sense of the sense o

confounded by sex (BMI, tobacco usage, alcohol consumption, lipid-lowering
 medication and diabetic medication). To properly model all gene by environment
 interactions⁸⁹, we fitted the following model per clump lead variant and associated
 metabolic phenotype, including the same set of covariates used in the original GWAS:

NMR phenotype ~ SNP + confounder + sex + age + fasting duration + PC1-10 + SNP*sex + SNP*confounder

+ sex*confounder + error

- 864
- 865 866
- 867

868 Causal gene assignment

869

870 To assign candidate genes for all metabolite-QTLs residing outside the MHC region, we first collected annotations for each genetic variant or proxies thereof ($r^2 > 0.6$), including 871 1) distance to the gene body and 2) putative functional consequences based on the 872 873 Variant Effect Predictor (VEP) tool offered by Ensembl. We further collated up to 10 closest genes within a 2 Mb window and subsequent gene features such as: 1) eQTL 874 875 evidence for a given variant-gene pair for each tissue available in the eQTL Catalogue 876 release 7⁹⁰, 2) evidence of being annotated as metabolic in the MGI or Orphanet databases as defined in ProGem²⁵, 3) evidence of being listed in the OMIM database⁴³ 4) 877 878 and evidence of being an already assigned drug target in Open Targets⁹¹ clinical stage III 879 and IV.

880

881 With no universally accepted standard for variant-to-gene assignments, we relied on 882 prior biological and genomic information to create three sets of "putative true positive" 883 (PTP) set: 1) genes annotated as part of a cholesterol pathway in the KEGG⁹² or 884 REACTOME⁹³ database (n=6791, 722 unique SNPs), 2) genes annotated as part of a lipid 885 pathway (n=5670, 603 unique SNPs) and 3) genes annotated as part of an amino acid-886 related pathway (n=8349, 895 unique SNPs). We used all fine-mapped SNPs associated 887 with metabolites classified in the respective NMR metabolite class (Cholesterol: 888 Cholesterol, Cholesteryl esters, Free cholesterol; Lipid: Total lipids, other lipids, Relative 889 lipid concentration, Phospholipids); Amino Acid: Amino acid) in the PTP set and used 890 overlapping SNPs in only one PTP set. The dataset was split in a 7:3 ratio to obtain training 891 and test sets without overlapping variants. We trained a Random Forest classifier using 892 5-fold cross-validation with implemented subsampling to account for the unbalanced 893 datasets. The implementation was carried out using python scikit-learn v1.4.1. We used 894 the balanced accuracy score to choose the best-performing forest from each training set. 895 Subsequently, we used the best-performing Random Forest classifiers from each PTP set 896 to assign candidate scores for all putative effector genes across the entire set of 897 metabolite-QTLs. We then calculated the median score of these classifiers and selected 898 the highest-scoring gene as the assigned gene for the variant. Within each PTP set, we 899 omitted features used to define true positive sets. Each of the three classifiers exhibited

consistent performance with a mean ROC AUC of 0.80 and a mean balanced accuracyscore of 0.69 (Supplementary Fig. 16).

902

903 To provide another layer of evidence for assignment of causal genes at metabolic loci, we 904 performed cis-colocalisation with protein targets measured in the independent Fenland 905 study²⁸. Cis (e.g. gene body \pm 500kb) summary statistics were preprocessed using MungeSumStats⁹⁴. To relax the single causal variant assumption, we employed a 906 907 colocalization approach where we fine-mapped all traits with SuSiE and then performed colocalization among all credible sets using functionality of the `coloc` (v5.2.3)^{95,96} and 908 909 `susieR` (v0.12.35)⁸⁵ R packages. For this, we set the prior probability that a SNP is 910 associated with both traits to 5x10⁻⁶ and restricted the maximum number of credible sets 911 for the outcome data to 5⁹⁵.

- 912
- 913 Tissue enrichment of metabolic loci
- 914

We tested whether genes proximal to metabolic loci and assigned effector genes were
enriched in tissue compartments by leveraging data from the Human Protein Atlas⁹⁷.
Specifically, we used a two-sided Fisher's test whether metabolic genes were enriched
among tissue-specific genes (tissue-enriched or tissue-enhanced as defined by the

- 919 Protein Atlas) against all protein-coding genes as background.
- 920

921 Pleiotropy assignment and overlap with the GWAS catalog

922

923 To assign modes of pleiotropy for each mQTL, we first clumped lead credible set variants 924 across NMR measures by LD, collating variants with $r^2 \ge 0.6$ as a single signal, referred to 925 hereafter as 'mQTL. This was done based on dosage files of all unrelated White European 926 UKB participants and implemented with the *igraph* (v.2.0.1.1) package in R. For each 927 mQTL, we then computed all possible Pearson correlation coefficients among 928 associated NMR measures. To classify each mQTL-group, generated two metrics: 1) the 929 25th percentile of all correlations among associated NMR measures, and 2) the Pearson 930 correlation coefficient between the association strengths for each measure (-log₁₀(pvalue) and its correlation coefficient with the most strongly associated measure within 931 932 the mQTL. The latter is a measure to what extend the association between NMR 933 measures at a given locus ('pleiotropy') can be explained by being correlated with the 934 most proximal associated measure. Based on opposing those two measures for all 935 mQTLs we opted to threshold each at 0.6 to define the following five groups: 1) 'specific' 936 mQTLs associated with only \leq 3 highly correlated NMR measures (rho \geq 0.6), 2) 'pathway 937 pleiotropic' mQTLs associated with highly correlated NMR measures (rho>0.6) that also followed the described association pattern (rho≥0.6), 3) 'proportional pleiotropic' mQTL 938 939 groups associated with, in part, uncorrelated NMR measures but highly correlated 940 association statistics (rho≥0.6), 4) 'disproportional pleiotropic' mQTLs associated with 941 highly correlated NMR measures (rho≥0.6), but without evidence that this translated into 942 a correlation of association statistics (rho<0.6), and 5) all remaining mQTLs as 'unspecific 943 pleiotropic' groups.

945 To quantify the extent to which our pleiotropy assignment extends beyond the NMR 946 measured analysed here, we intersected mOTLs and proxies thereof with results reported 947 in the GWAS catalog (download: 20/05/2024). We first pruned GWAS catalog entries for 948 those with mapped traits (to minimize double counting), results that met genome-wide 949 significance (p<5x10⁻⁸) and had location information available. We further dropped 950 results similar to NMR measures based on broad EFO terms (e.g., EFO:0005105 and child 951 terms indicating 'lipid or lipoprotein measurement'). To further account for traits mapping 952 to similar categories, we iteratively traced back mapped EFO terms to broader parent 953 terms. We finally classified mQTLs to be 'specific' in the GWAS catalog, if they associated 954 with less than five parent EFO-terms and 'unspecific' otherwise. This information was 955 primarily used to define instruments for Mendelian randomization analysis.

956

957 Integration of metabolomic measurements with cardiovascular

958 endpoints

959

We next aimed to utilize the mQTLs to investigate the shared genetic basis of the 249 NMR 960 961 and 25 selected cardiovascular disease (CVD) traits. We utilized public databases (GWAS 962 Catalog, openGWAS, CVD-KP) to collect CVD data comprising the largest currently 963 publicly available GWASs on coronary artery disease and myocardial infarction, angina 964 pectoris, aortic aneurysm, heart failure and stroke, peripheral arterial disease including 965 2-5 subtypes for each phenotype. An additional 10 CVD traits had no subtype data 966 available (Supplementary Table 13) Data was harmonized and if necessary, lifted over 967 to GRCh37 using the `MungeSumstats` (v1.13.2) R package⁹⁴. We queried mQTL lead 968 variants and proxies in strong LD (r²>0.8; LD backbone based on UK Biobank, as described 969 above) of each NMR trait in each region and corresponding summary statistics for each CVD 970 trait.

971

To investigate `variant` effects on NMR metabolite concentrations and CVD outcomes,
we performed statistical colocalization screens for all combinations of the NMR traits in
regions with at least one credible set and CVD traits with matching summary statistics⁹⁸.
We applied statistical colocalization as described before (see 'Causal gene assignment').

977 To estimate `level` effects of NMR metabolite concentrations on CVD outcomes, we 978 performed Mendelian Randomization analysis using the `TwoSampleMR` package 979 (v0.5.1), implementing the inverse-variance weighted and the MR-Egger methods. We 980 used all 249 NMR metabolites as exposure variables, the 25 CVDs as outcome variables 981 and assessed separately four sets of instruments: 1) sentinel variants, 2) lead credible 982 set variants, 3) lead credible set variants restricted for molecular pleiotropy (e.g. 983 'pathway pleiotropy') and 4) lead credible set variants restricted for both molecular and 984 phenotypic pleiotropy. We used the Wald ratio method to estimate the effect of NMR 985 concentrations on CVD outcomes using only single genetic variants⁹⁹. We used MR Egger 986 to test for evidence of a pleiotropic association, an intercept p-value of p> 0.0001 987 indicating evidence of no pleiotropy and checked for concordance between the effect 988 estimates of IVW-MR, MR-Egger and single genetic variant MR. We controlled the false discovery rate (FDR) at FDR=5% ¹⁰⁰. To further limit the possible extend of pleiotropic 989

- associations, we only reported `level effects` passing these filters in the variant sets 24, prioritizing the association in the more stringent variant set.
- 992

993 The overlap of `locus effects` showing no `disproportional pleiotropy` according to the 994 section Pleiotropy assignment and overlap with the GWAS catalog as well as a 995 significant single variant MR (FDR=5%) and `level effects` calculated from metabolite-996 specific or metabolite- and phenome-specific variants was used to identify gene-997 metabolite pairs associated with cardiovascular disease risk independent of LDLmetabolism. We considered loci as independent from LDL-metabolism if they did not 998 999 associate with clinical LDL-cholesterol at the locus with $p < 2.0 \times 10^{-10}$ and the effect 1000 estimate of any variant on clinical LDL-C ranked upwards the 80th percentile of all effect 1001 estimates at the locus.

- 1002 Rare Variant Analyses with whole exome sequencing data
- 1003

1004 Whole Exome Sequencing data QC

An in-depth description of whole exome sequencing, including experimental details,
 variant calling, and standard quality control measures for the UK Biobank, has been
 extensively reported by Backman et al.¹⁰¹. We performed additional quality control (QC)
 steps at the UKB Research Analysis Platform (RAP; <u>https://ukbiobank.dnanexus.com/</u>).

1009

1010 We employed bcftools (v1.15.1) to process population-level Variant Call Format (pVCF) files. Initially, we normalised the data using the reference sequence GRCh38 build, 1011 followed by splitting multi-allelic variants. Subsequently, we conducted QC on these 1012 1013 variants using a set of parameters outlined below to filter high-quality variants for 1014 downstream genetic analyses. Genotypes for SNPs were set to missing if the read depth 1015 was less than 7 (or less than 10 for INDELs) or if the genotype quality was below 20. 1016 Furthermore, we excluded variants if the allele balance (AB) was less than 0.25 or greater 1017 than 0.8 in heterozygous carriers.

- 1018
- Finally, we computed the missingness rate for each variant and excluded those withmissing values in over 50% of the participants.
- 1021

1022 Variant Annotation and Gene burden Masks

1023 Variants were annotated using ENSEMBL Variant Effect Predictor (VEP)¹⁰² (v106.1) with 1024 the most severe consequence for each variant chosen across all protein-coding 1025 transcripts. We further utilized additional plugins REVEL¹⁰³, CADD v1.6¹⁰⁴, and LOFTEE¹⁰⁵, 1026 for variant annotation. Based on these scores we defined six partially overlapping variant 1027 masks: 1) high-confidence predicted loss-of-function (pLOF, based on LOFTEE and 1028 includes stop-gained, splice site disrupting, and frameshift variants), 2) any pLOF 1029 assigned high impact by VEP, 3) pLOF and high-impact missense variants (CADD score > 1030 20 oe REVEL score > 0.5), 4) pLOF and any missense variants, 5) only high-impact 1031 variants, and 6) any missense variants but not pLOF. We tested synonymous variants separately as a negative control. We tested each mask in different minor allele frequencybins, using 0.5% and 0.005% as thresholds.

1034

1035 We performed rare variant association testing (RVAT) using WES data across 249 1036 quantitative NMR phenotypes using REGENIE (v3.1.1) via the DNAnexus Swiss Army Knife 1037 tool (v4.9.1). Similar to common variant GWASs, we used a two-step approach by REGENIE. However, we additionally generated step1 LOCO files with and without 1038 1039 adjusting for common signals via a polygenic score (PGS) in the RVAT models per 1040 phenotype. In practice, we computed a PGS for each phenotype using effect sizes of lead 1041 variants from the GWAS summary statistics and corresponding dosages of variants from 1042 imputed data. All RVAT models were then adjusted for PGS in addition to age, biological 1043 sex, fasting duration and the first ten genetic PCs. We first performed aggregated gene 1044 burden testing across for 19,026 genes using a set of masks as defined above. For the 1045 gene burden testing we used aggregated Cauchy association test (ACAT) to estimate a p-1046 value for each gene across all combinations of masks and allele frequency bins. ACAT first computes p-values for all sets defined by various masks within a gene and then takes 1047 1048 these p-values as input to compute one p-value for the respective gene via a well 1049 approximated Cauchy distribution.

1050

1051 We have also performed single variant association testing for exonic variants commonly 1052 referred to as exome wide association study (ExWAS). For the ExWAS, we only tested 1053 variants with MAC >5 and reported results for variants with a MAF < 0.0005. We have 1054 performed these analyses in individuals of White Europeans, British African and British 1055 South Asian ancestry.

1056

1057 We considered findings as robust, if they passed multiple testing corrected statistical 1058 significance (gene burden: $p<1.2x10^{-8}$ [corrected for the number of genes x number of 1059 traits]; ExWAS: $p<2.0 \times 10^{-10}$ [same as for common variant GWAS, conventional genome-1060 wide significance corrected for the number of traits]) in both the model with and without 1061 adjusting for the common variant PGS and effect sizes did not differ by more than 20% 1062 between these models, since this might otherwise indicate that rare variant findings 1063 cannot clearly distinguished from common variant effects.

1064

1065 Phenotype definition

To systematically test for phenotypic consequences of genes identified through rare variant analysis, we collated 626 disease entities following previous work¹ by aggregating information from self-report, hospital episode statistics, death certificates, and primary care data (45% of the UKB population). Each of the disease entities had at least one common variant finding passing statistical significance, and we employed a similar analysis workflow using REGENIE as described for NMR measures but using logistic regression with saddle point approximation.

1074 Integration of OMIM (Online Mendelian Inheritance in Man)

1075 We downloaded the OMIM gene – disease list (09/11/2023) and kept 7,327 unique entries 1076 after filtering for gene entries with high confidence (level 3). We computed the 1077 enrichment of genes associated with any NMR measure from rare variant or gene burden 1078 analysis against a background of 19,989 protein coding genes using Fisher's exact test. 1079

- 1080 Mendelian Randomisation analyses
- 1081

We performed a phenome-wide Mendelian Randomisation screen using outcome summary statistics from the independent FinnGenn⁶⁸ cohort, release 11 (June 2024). We assessed only outcomes with genome-wide significant signals (5 x 10⁻⁸), yielding 1394 phenotypic outcomes. We selected 21 non-lipid NMR biomarkers as exposure variables and assessed separately four sets of instruments as described previously for the cardiovascular Mendelian Randomisation analyses. We included two well-characterized lipid biomarkers (LDL-C and ApoB) as positive controls in the MR analyses.

1089

1090 We performed MR using the TwoSampleMR package (v0.5.1), implementing the inverse-1091 variance weighted and the MR-Egger methods. We discarded results with MR Egger p < 1092 0.001, Cochran's Q p-value < 1.0 x 10^{-6} and results where the estimated effect was 1093 directionally discordant between the IVW and Egger methods.

- 1094 References
- 1095
- 1096 1. Surendran, P. et al. Rare and common genetic determinants of metabolic
- 1097 individuality and their effects on human health. *Nat. Med.* **28**, 2321–2332 (2022).
- 1098 2. Lotta, L. A. *et al*. A cross-platform approach identifies genetic regulators of human
- 1099 metabolism and health. *Nat. Genet.* **53**, 54–64 (2021).
- 1100 3. Karjalainen, M. K. *et al*. Genome-wide characterization of circulating metabolic
- 1101 biomarkers. *Nature* **628**, 130–138 (2024).
- 1102 4. Kettunen, J. *et al.* Genome-wide association study identifies multiple loci influencing
- 1103 human serum metabolite levels. *Nat. Genet.* **44**, 269–276 (2012).
- 1104 5. Chen, Y. et al. Genomic atlas of the plasma metabolome prioritizes metabolites
- 1105 implicated in human diseases. *Nat. Genet.* **55**, 44–53 (2023).

- 1106 6. Nag, A. et al. Effects of protein-coding variants on blood metabolite measurements
- and clinical biomarkers in the UK Biobank. *Am. J. Hum. Genet.* **110**, 487–498 (2023).
- 1108 7. Long, T. et al. Whole-genome sequencing identifies common-to-rare variants
- associated with human blood metabolites. *Nat. Genet.* **49**, 568–578 (2017).
- 1110 8. Shin, S.-Y. *et al*. An atlas of genetic influences on human blood metabolites. *Nat*.
- 1111 Genet. **46**, 543–550 (2014).
- 1112 9. Tambets, R. *et al.* Genome-wide association study for circulating metabolites in
- 1113 619,372 individuals. *medRxiv* (2024) doi:10.1101/2024.10.15.24315557.
- 1114 10. Yin, X. et al. Genome-wide association studies of metabolites in Finnish men
- 1115 identify disease-relevant loci. *Nat. Commun.* **13**, 1644 (2022).
- 1116 11. Van Der Meer, D. et al. Pleiotropic and sex-specific genetic architecture of
- 1117 circulating metabolic markers. *medRxiv* (2024) doi:10.1101/2024.07.30.24311254.
- 1118 12. Khan, A. et al. Metabolic gene function discovery platform GeneMAP identifies
- 1119 SLC25A48 as necessary for mitochondrial choline import. *Nat. Genet.* (2024)
- 1120 doi:10.1038/s41588-024-01827-2.
- 1121 13. Schlosser, P. et al. Genetic studies of paired metabolomes reveal enzymatic and
- 1122 transport processes at the interface of plasma and urine. *Nat. Genet.* **55**, 995–1008
- 1123 (2023).
- 1124 14. Love-Gregory, L. et al. Variants in the CD36 gene associate with the metabolic
- syndrome and high-density lipoprotein cholesterol. *Hum. Mol. Genet.* 17, 1695–1704
 (2008).
- 1127 15. Adiyaman, S. C. et al. Congenital generalized lipodystrophy type 4 due to a novel
- 1128 PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution. J.
- 1129 Pediatr. Endocrinol. Metab. JPEM **35**, 946–952 (2022).

- 1130 16. Mauvais-Jarvis, F. Sex differences in energy metabolism: natural selection,
- 1131 mechanisms and consequences. *Nat. Rev. Nephrol.* **20**, 56–69 (2024).
- 1132 17. Gerdts, E. & Regitz-Zagrosek, V. Sex differences in cardiometabolic disorders.
- 1133 Nat. Med. 25, 1657–1666 (2019).
- 1134 18. Wittemans, L. B. L. et al. Assessing the causal association of glycine with risk of
- 1135 cardio-metabolic diseases. *Nat. Commun.* **10**, 1060 (2019).
- 1136 19. Mittelstrass, K. et al. Discovery of sexual dimorphisms in metabolic and genetic
- 1137 biomarkers. *PLoS Genet.* **7**, e1002215 (2011).
- 1138 20. Koprulu, M. et al. Similar and different: systematic investigation of
- 1139 proteogenomic variation between sexes and its relevance for human diseases.
- 1140 *medRxiv* (2024) doi:10.1101/2024.02.16.24302936.
- 1141 21. Michos, E. D., McEvoy, J. W. & Blumenthal, R. S. Lipid Management for the
- 1142 Prevention of Atherosclerotic Cardiovascular Disease. N. Engl. J. Med. 381, 1557–

1143 1567 (2019).

1144 22. Graham, S. E. et al. The power of genetic diversity in genome-wide association

1145 studies of lipids. *Nature* **600**, 675–679 (2021).

- 1146 23. BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C. & Hobbs, H. H. Accumulation of
- 1147 PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. *Proc. Natl.*
- 1148 Acad. Sci. U. S. A. **116**, 9521–9526 (2019).
- 1149 24. Johnson, S. M. et al. PNPLA3 is a triglyceride lipase that mobilizes
- 1150 polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-
- density lipoprotein. *Nat. Commun.* **15**, 4847 (2024).
- 1152 25. Stacey, D. et al. ProGeM: a framework for the prioritization of candidate causal
- 1153 genes at molecular quantitative trait loci. *Nucleic Acids Res.* **47**, e3 (2019).

- 1154 26. Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related
- 1155 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.

1156 Nat. Genet. **52**, 680–691 (2020).

- 1157 27. Donaldson, J. G. & Jackson, C. L. ARF family G proteins and their regulators: roles
- 1158 in membrane transport, development and disease. *Nat. Rev. Mol. Cell Biol.* **12**, 362–

1159 375 (2011).

- 1160 28. Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases.
 1161 Science **374**, eabj1541 (2021).
- 1162 29. Pellegrinelli, V. et al. Dysregulation of macrophage PEPD in obesity determines
- adipose tissue fibro-inflammation and insulin resistance. *Nat. Metab.* **4**, 476–494
- 1164 (2022).
- 1165 30. Wang, Q. et al. Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition:

a drug-target Mendelian randomization analysis. *Eur. Heart J.* **42**, 1160–1169 (2021).

- 1167 31. Hindy, G. et al. Rare coding variants in 35 genes associate with circulating lipid
- 1168 levels-A multi-ancestry analysis of 170,000 exomes. *Am. J. Hum. Genet.* **109**, 81–96
 (2022).
- Sjouke, B., Balak, D. M. W., Beuers, U., Ratziu, V. & Stroes, E. S. G. Is mipomersen
 ready for clinical implementation? A transatlantic dilemma. *Curr. Opin. Lipidol.* 24,
- 1172 301–306 (2013).
- 1173 33. Spracklen, C. N. *et al.* Identification of type 2 diabetes loci in 433,540 East Asian
- 1174 individuals. *Nature* **582**, 240–245 (2020).
- 1175 34. Rhee, E. P. *et al.* An exome array study of the plasma metabolome. *Nat.*

1176 *Commun.* **7**, 12360 (2016).

- 1177 35. Chen, X., Gu, X. & Zhang, H. Sidt2 regulates hepatocellular lipid metabolism
- 1178 through autophagy. J. Lipid Res. **59**, 404–415 (2018).
- 1179 36. Sampieri, A., Asanov, A., Méndez-Acevedo, K. M. & Vaca, L. SIDT2 Associates
- 1180 with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes.
- 1181 *Cells* **12**, 2353 (2023).
- 1182 37. Jaiswal, S. et al. Clonal Hematopoiesis and Risk of Atherosclerotic
- 1183 Cardiovascular Disease. N. Engl. J. Med. **377**, 111–121 (2017).
- 1184 38. Weiner, D. J. et al. Polygenic architecture of rare coding variation across 394,783
- 1185 exomes. *Nature* **614**, 492–499 (2023).
- 1186 39. Szeri, F. et al. The membrane protein ANKH is crucial for bone mechanical
- 1187 performance by mediating cellular export of citrate and ATP. *PLoS Genet.* **16**,
- 1188 e1008884 (2020).
- 1189 40. Chroni, A. & Kardassis, D. HDL Dysfunction Caused by Mutations in apoA-I and
- 1190 Other Genes that are Critical for HDL Biogenesis and Remodeling. *Curr. Med. Chem.*
- 1191 **26**, 1544–1575 (2019).
- 1192 41. Tilly-Kiesi, M. et al. ApoA-I_{Helsinki} (Lys₁₀₇→0) Associated With Reduced HDL
- 1193 Cholesterol and LpA-I:A-II Deficiency. *Arterioscler. Thromb. Vasc. Biol.* **15**, 1294–13061194 (1995).
- 1195 42. Zanoni, P. & Von Eckardstein, A. Inborn errors of apolipoprotein A-I metabolism:
- 1196 implications for disease, research and development. *Curr. Opin. Lipidol.* **31**, 62–70
- 1197 (2020).
- 1198 43. Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F. & Hamosh, A.
- 1199 OMIM.org: Online Mendelian Inheritance in Man (OMIM[®]), an online catalog of human
- 1200 genes and genetic disorders. *Nucleic Acids Res.* **43**, D789–D798 (2015).

- 1201 44. Horiki, M. et al. Smad6/Smurf1 overexpression in cartilage delays chondrocyte
- 1202 hypertrophy and causes dwarfism with osteopenia. J. Cell Biol. **165**, 433–445 (2004).
- 1203 45. Zhang, F., Sodroski, C., Cha, H., Li, Q. & Liang, T. J. Infection of Hepatocytes With
- 1204 HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of
- 1205 Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.
- 1206 *Gastroenterology* **152**, 257-270.e7 (2017).
- 1207 46. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets
- 1208 through human genetics. *Nat. Rev. Drug Discov.* **12**, 581–594 (2013).
- 1209 47. Hoogeveen, R. C. & Ballantyne, C. M. Residual Cardiovascular Risk at Low LDL:
- 1210 Remnants, Lipoprotein(a), and Inflammation. *Clin. Chem.* **67**, 143–153 (2021).
- 1211 48. Aragam, K. G. et al. Discovery and systematic characterization of risk variants
- 1212 and genes for coronary artery disease in over a million participants. *Nat. Genet.* 54,

1213 1803–1815 (2022).

- 1214 49. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human
 1215 phenotypes. *Nat. Genet.* 53, 1415–1424 (2021).
- 1216 50. Roychowdhury, T. *et al.* Genome-wide association meta-analysis identifies risk
- 1217 loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. *Nat*.
- 1218 Genet. **55**, 1831–1842 (2023).
- 1219 51. Roychowdhury, T. et al. Regulatory variants in TCF7L2 are associated with
- 1220 thoracic aortic aneurysm. Am. J. Hum. Genet. **108**, 1578–1589 (2021).
- 1221 52. Miyazawa, K. et al. Cross-ancestry genome-wide analysis of atrial fibrillation
- 1222 unveils disease biology and enables cardioembolic risk prediction. *Nat. Genet.* **55**,

1223 187–197 (2023).

- 1224 53. Yu Chen, H. et al. Dyslipidemia, inflammation, calcification, and adiposity in
- 1225 aortic stenosis: a genome-wide study. *Eur. Heart J.* **44**, 1927–1939 (2023).
- 1226 54. Zhou, W. et al. Global Biobank Meta-analysis Initiative: Powering genetic
- 1227 discovery across human disease. *Cell Genomics* **2**, 100192 (2022).
- 1228 55. Kavousi, M. et al. Multi-ancestry genome-wide study identifies effector genes
- 1229 and druggable pathways for coronary artery calcification. *Nat. Genet.* **55**, 1651–1664
- 1230 (2023).
- 1231 56. Henry, A. et al. Mapping the aetiological foundations of the heart failure
- 1232 spectrum using human genetics. *medRxiv* (2023) doi:10.1101/2023.10.01.23296379.
- 1233 57. Ishigaki, K. et al. Large-scale genome-wide association study in a Japanese
- 1234 population identifies novel susceptibility loci across different diseases. *Nat. Genet.*
- 1235 **52**, 669–679 (2020).
- 1236 58. Mishra, A. et al. Stroke genetics informs drug discovery and risk prediction
- 1237 across ancestries. *Nature* **611**, 115–123 (2022).
- 1238 59. Roselli, C. et al. Genome-wide association study reveals novel genetic loci: a
- new polygenic risk score for mitral valve prolapse. *Eur. Heart J.* **43**, 1668–1680 (2022).
- 1240 60. Hartiala, J. A. et al. Genome-wide analysis identifies novel susceptibility loci for
- 1241 myocardial infarction. *Eur. Heart J.* **42**, 919–933 (2021).
- 1242 61. van Zuydam, N. R. *et al*. Genome-Wide Association Study of Peripheral Artery
- 1243 Disease. Circ. Genomic Precis. Med. 14, e002862 (2021).
- 1244 62. Adlam, D. et al. Genome-wide association meta-analysis of spontaneous
- 1245 coronary artery dissection identifies risk variants and genes related to artery integrity
- 1246 and tissue-mediated coagulation. *Nat. Genet.* **55**, 964–972 (2023).

- 1247 63. Pérez-Gutiérrez, L. & Ferrara, N. Biology and therapeutic targeting of vascular
- 1248 endothelial growth factor A. *Nat. Rev. Mol. Cell Biol.* **24**, 816–834 (2023).
- 1249 64. Velagapudi, S. et al. VEGF-A Regulates Cellular Localization of SR-BI as Well as
- 1250 Transendothelial Transport of HDL but Not LDL. Arterioscler. Thromb. Vasc. Biol. 37,
- 1251 794–803 (2017).
- 1252 65. Chen, H. X. & Cleck, J. N. Adverse effects of anticancer agents that target the
- 1253 VEGF pathway. *Nat. Rev. Clin. Oncol.* **6**, 465–477 (2009).
- 1254 66. Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G. & Goldberg, I. J.
- 1255 Addressing dyslipidemic risk beyond LDL-cholesterol. J. Clin. Invest. **132**, e148559
- 1256 (2022).
- 1257 67. Zanoni, P. et al. Rare variant in scavenger receptor BI raises HDL cholesterol and
- 1258 increases risk of coronary heart disease. *Science* **351**, 1166–1171 (2016).
- 1259 68. Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped
- isolated population. *Nature* **613**, 508–518 (2023).
- 1261 69. Ritchie, S. C. *et al.* The Biomarker GlycA Is Associated with Chronic Inflammation
- and Predicts Long-Term Risk of Severe Infection. *Cell Syst.* **1**, 293–301 (2015).
- 1263 70. Lotta, L. A. et al. Genetic Predisposition to an Impaired Metabolism of the
- 1264 Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian
- 1265 Randomisation Analysis. *PLoS Med.* **13**, e1002179 (2016).
- 1266 71. Zhao, Y. et al. Small rodent models of atherosclerosis. Biomed. Pharmacother.
- 1267 Biomedecine Pharmacother. **129**, 110426 (2020).
- 1268 72. Shim, J., Al-Mashhadi, R. H., Sørensen, C. B. & Bentzon, J. F. Large animal models
- 1269 of atherosclerosis--new tools for persistent problems in cardiovascular medicine. J.
- 1270 Pathol. 238, 257–266 (2016).

- 1271 73. Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in
- 1272 complex traits. *Nat. Genet.* **51**, 1339–1348 (2019).
- 1273 74. Smith, C. J. et al. Integrative analysis of metabolite GWAS illuminates the
- 1274 molecular basis of pleiotropy and genetic correlation. *eLife* **11**, e79348 (2022).
- 1275 75. Julkunen, H. et al. Atlas of plasma NMR biomarkers for health and disease in
- 1276 118,461 individuals from the UK Biobank. *Nat. Commun.* **14**, 604 (2023).
- 1277 76. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic
- 1278 data. *Nature* **562**, 203–209 (2018).
- 1279 77. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes
- 1280 of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779
- 1281 (2015).
- 1282 78. Karczewski, K. J. et al. Pan-UK Biobank GWAS improves discovery, analysis of
- 1283 genetic architecture, and resolution into ancestry-enriched effects. *medRxiv* (2024)
- 1284 doi:10.1101/2024.03.13.24303864.
- 1285 79. Würtz, P. et al. Quantitative Serum Nuclear Magnetic Resonance Metabolomics
- in Large-Scale Epidemiology: A Primer on -Omic Technologies. *Am. J. Epidemiol.* 186,
 1084–1096 (2017).
- 1288 80. Ritchie, S. C. *et al.* Quality control and removal of technical variation of NMR
 1289 metabolic biomarker data in ~120,000 UK Biobank participants. *Sci. Data* **10**, 64
- 1290 (2023).
- Buuren, S. van & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by
 Chained Equations in R. J. Stat. Softw. 45, 1–67 (2011).
- 1293 82. Mbatchou, J. *et al*. Computationally efficient whole-genome regression for
- 1294 quantitative and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

- 1295 83. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- 1296 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 1297 84. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
- 1298 polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 1299 85. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to
- 1300 variable selection in regression, with application to genetic fine mapping. J. R. Stat.
- 1301 Soc. Ser. B Stat. Methodol. 82, 1273–1300 (2020).
- 1302 86. Wakefield, J. Bayes factors for genome-wide association studies: comparison
- 1303 with P-values. Genet. Epidemiol. **33**, 79–86 (2009).
- 1304 87. Rossen, J. *et al*. MultiSuSiE improves multi-ancestry fine-mapping in All of Us
- 1305 whole-genome sequencing data. *medRxiv* (2024) doi:10.1101/2024.05.13.24307291.
- 1306 88. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and
 1307 richer datasets. *GigaScience* 4, 7 (2015).
- 1308 89. Keller, M. C. Gene × environment interaction studies have not properly controlled
- 1309 for potential confounders: the problem and the (simple) solution. *Biol. Psychiatry* **75**,
- 1310 18–24 (2014).
- 1311 90. Kerimov, N. *et al.* A compendium of uniformly processed human gene expression
- and splicing quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).
- 1313 91. Ochoa, D. et al. The next-generation Open Targets Platform: reimagined,
- 1314 redesigned, rebuilt. *Nucleic Acids Res.* **51**, D1353–D1359 (2023).
- 1315 92. Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids*1316 *Res.* 28, 27–30 (2000).
- 1317 93. Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids
- 1318 *Res.* **52**, D672–D678 (2024).

- 1319 94. Murphy, A. E., Schilder, B. M. & Skene, N. G. MungeSumstats: a Bioconductor
- 1320 package for the standardization and quality control of many GWAS summary
- 1321 statistics. *Bioinformatics* **37**, 4593–4596 (2021).
- 1322 95. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
- 1323 colocalisation analyses. *PLOS Genet.* **16**, e1008720 (2020).
- 1324 96. Wallace, C. A more accurate method for colocalisation analysis allowing for
- 1325 multiple causal variants. *PLOS Genet.* **17**, e1009440 (2021).
- 1326 97. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347,
- 1327 1260419 (2015).
- 1328 98. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of
- Genetic Association Studies Using Summary Statistics. *PLoS Genet.* 10, e1004383
 (2014).
- 1331 99. Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable
- 1332 estimators for Mendelian randomization. *Stat. Methods Med. Res.* **26**, 2333–2355
- 1333 (2017).
- 1334 100. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical
- and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57,
 289–300 (1995).
- 1337 101. Backman, J. D. *et al*. Exome sequencing and analysis of 454,787 UK Biobank
- 1338 participants. *Nature* **599**, 628–634 (2021).
- 1339 102. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122
 1340 (2016).
- 1341 103. Ioannidis, N. M. et al. REVEL: An Ensemble Method for Predicting the
- 1342 Pathogenicity of Rare Missense Variants. Am. J. Hum. Genet. 99, 877–885 (2016).

- 1343 104. Kircher, M. et al. A general framework for estimating the relative pathogenicity of
- 1344 human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
- 1345 105. Karczewski, K. J. et al. The mutational constraint spectrum quantified from
- 1346 variation in 141,456 humans. *Nature* **581**, 434–443 (2020).